129 related articles for article (PubMed ID: 38406980)
1. Operative trends following the adoption of nonoperative management of rectal cancer.
Brewer J; Kamara M; Huebner M; Taxakis E; Grajewski K; Ramm C; Cleary RK
J Surg Oncol; 2024 May; 129(6):1139-1149. PubMed ID: 38406980
[TBL] [Abstract][Full Text] [Related]
2. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
[No Abstract] [Full Text] [Related]
3. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
4. Outcomes of Patients With Local Regrowth After Nonoperative Management of Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Cotti GC; Pandini RV; Braghiroli OFM; Nahas CSR; Bustamante-Lopez LA; Marques CFS; Imperiale AR; Ribeiro U; Salvajoli B; Hoff PM; Nahas SC
Dis Colon Rectum; 2022 Mar; 65(3):333-339. PubMed ID: 34775415
[TBL] [Abstract][Full Text] [Related]
5. [Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial].
Wang L; Zhao YM; Sun TT; Xu YL; Li SJ; Zhang XY; Cai Y; Li YH; Li ZW; Chen PJ; Peng YF; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):258-265. PubMed ID: 32192305
[No Abstract] [Full Text] [Related]
6. Early results from implementation of a 'watch and wait' protocol for complete clinical response following chemoradiotherapy for rectal cancer.
Balasuriya HD; Timon C; Entriken F; Neely D; Herron J; Tang C; Van Hazel G; Warner MW
ANZ J Surg; 2022 Nov; 92(11):2961-2967. PubMed ID: 35841184
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of the watch-and-wait strategy versus total mesorectal excision for rectal cancer exhibiting complete clinical response after neoadjuvant chemoradiotherapy.
Yu G; Lu W; Jiao Z; Qiao J; Ma S; Liu X
World J Surg Oncol; 2021 Oct; 19(1):305. PubMed ID: 34663341
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of real world 'watch and wait' data for rectal cancer after neoadjuvant chemoradiotherapy.
Simpson G; Hopley P; Wilson J; Day N; Haworth A; Montazeri A; Smith D; Titu L; Anderson J; Agbamu D; Walsh C
Colorectal Dis; 2020 Nov; 22(11):1568-1576. PubMed ID: 32686268
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of rectal cancer patients who refuse surgery after incomplete clinical response to neoadjuvant therapy.
Labadie KP; Olson KA; Sun SH; Ituarte PHG; Hanna M; Zerhouni Y; Lai LL; Sentovich SM; Kaiser AM; Melstrom KA
J Surg Oncol; 2024 May; 129(6):1131-1138. PubMed ID: 38396372
[TBL] [Abstract][Full Text] [Related]
10. Intentional Watch and Wait or Organ Preservation Surgery Following Neoadjuvant Chemoradiotherapy Plus Consolidation CAPEOX for MRI-defined Low-risk Rectal Cancer: Findings From a Prospective Phase 2 Trial (PKUCH-R01 Trial, NCT02860234).
Wang L; Zhang XY; Zhao YM; Li SJ; Li ZW; Sun YS; Wang WH; Wu AW;
Ann Surg; 2023 Apr; 277(4):647-654. PubMed ID: 35766394
[TBL] [Abstract][Full Text] [Related]
11. Watch and Wait Approach After Neoadjuvant Chemoradiotherapy in Rectal Cancer: Initial Experience in the Indian subcontinent.
Engineer R; Saklani A; D'souza A; Arya S; Kumar S; Ostwal V; Ramaswamy A; Chopra S; Patil P
Indian J Surg Oncol; 2021 Dec; 12(4):664-670. PubMed ID: 35110885
[TBL] [Abstract][Full Text] [Related]
12. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Renehan AG; Malcomson L; Emsley R; Gollins S; Maw A; Myint AS; Rooney PS; Susnerwala S; Blower A; Saunders MP; Wilson MS; Scott N; O'Dwyer ST
Lancet Oncol; 2016 Feb; 17(2):174-183. PubMed ID: 26705854
[TBL] [Abstract][Full Text] [Related]
13. The impact of total neo-adjuvant treatment on nonoperative management in patients with locally advanced rectal cancer: The evaluation of 66 cases.
Asoglu O; Tokmak H; Bakir B; Demir G; Ozyar E; Atalar B; Goksel S; Koza B; Guven Mert A; Demir A; Guven K
Eur J Surg Oncol; 2020 Mar; 46(3):402-409. PubMed ID: 31955995
[TBL] [Abstract][Full Text] [Related]
14. [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center].
Wu A; Wang L; Du C; Peng Y; Yao Y; Zhao J; Zhan T; Cai Y; Li Y; Sun Y; Ji J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):417-424. PubMed ID: 28440523
[TBL] [Abstract][Full Text] [Related]
15. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
[No Abstract] [Full Text] [Related]
16. [Rational evaluation of the complete response after neoadjuvant therapy in locally advanced mid-low rectal cancer: the pros and cons of "watch and wait" strategy].
Gu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):507-513. PubMed ID: 31238630
[TBL] [Abstract][Full Text] [Related]
17. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
[TBL] [Abstract][Full Text] [Related]
18. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy.
Smith JJ; Strombom P; Chow OS; Roxburgh CS; Lynn P; Eaton A; Widmar M; Ganesh K; Yaeger R; Cercek A; Weiser MR; Nash GM; Guillem JG; Temple LKF; Chalasani SB; Fuqua JL; Petkovska I; Wu AJ; Reyngold M; Vakiani E; Shia J; Segal NH; Smith JD; Crane C; Gollub MJ; Gonen M; Saltz LB; Garcia-Aguilar J; Paty PB
JAMA Oncol; 2019 Apr; 5(4):e185896. PubMed ID: 30629084
[TBL] [Abstract][Full Text] [Related]
19. Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer.
Martens MH; Maas M; Heijnen LA; Lambregts DM; Leijtens JW; Stassen LP; Breukink SO; Hoff C; Belgers EJ; Melenhorst J; Jansen R; Buijsen J; Hoofwijk TG; Beets-Tan RG; Beets GL
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27509881
[TBL] [Abstract][Full Text] [Related]
20. ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group.
Fleischmann M; Diefenhardt M; Nicolas AM; Rödel F; Ghadimi M; Hofheinz RD; Greten FR; Rödel C; Fokas E;
Clin Transl Radiat Oncol; 2022 May; 34():99-106. PubMed ID: 35449546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
